Evaluating Tenaya Therapeutics, Inc. (NASDAQ: TNYA) as an equity investment involves weighing the high-risk, high-reward nature of clinical-stage biotechnology companies focused on cardiovascular gene therapies. While bullish analysts and specialized life science investors highlight the innovative potential of its cardiac pipeline and heart failure treatments, conservative investors face substantial risks including clinical trial uncertainty, high cash burn rates, and lack of immediate commercial product revenue.